Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-004433-17
    Sponsor's Protocol Code Number:124210
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-10-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-004433-17
    A.3Full title of the trial
    Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease
    Studio multicentrico, randomizzato, open-label, con endpoint valutati in cieco, di confronto tra la terapia di corticosteroidi più immunoglobulina intravenosa (IVIG) e aspirina, versus IVIG e aspirina, per la prevenzione di aneurismi dell’arteria coronarica nella malattia di Kawasaki
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Kawasaki Disease Coronary Artery Aneurysm Prevention trial
    Studio per la prevenzione dell’aneurisma dell’arteria coronarica della malattia di Kawasaki
    A.3.2Name or abbreviated title of the trial where available
    KD-CAAP
    KD-CAAP
    A.4.1Sponsor's protocol code number124210
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN71987471
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUNIVERSITY COLLEGE LONDON
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInnovative Medicine Initiative 2 Joint Undertaking
    B.4.2CountryEuropean Union
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCara Purvis
    B.5.2Functional name of contact pointClinical Trial Manager
    B.5.3 Address:
    B.5.3.1Street Address90 High Holborn
    B.5.3.2Town/ cityLondon
    B.5.3.3Post codeWC1V 6LJ
    B.5.3.4CountryUnited Kingdom
    B.5.6E-mailmrcctu.kdcaap@ucl.ac.uk
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisone
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISONE
    D.3.9.1CAS number 53-03-2
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive namePrednisone
    D.3.9.4EV Substance CodeSUB10020MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAspirin
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNACIDO ACETILSALICILICO
    D.3.9.1CAS number 50-78-2
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameAspirin
    D.3.9.4EV Substance CodeSUB12730MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisolone
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Soluble tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISOLONE
    D.3.9.1CAS number 50-24-8
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive namePrednisolone
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAspirina
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Soluble tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNACIDO ACETILSALICILICO
    D.3.9.1CAS number 50-78-2
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameAspirin
    D.3.9.4EV Substance CodeSUB12730MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisolone
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISOLONE
    D.3.9.1CAS number 50-24-8
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive namePrednisolone
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAspirina
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNACIDO ACETILSALICILICO
    D.3.9.1CAS number 50-78-2
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameAspirin
    D.3.9.4EV Substance CodeSUB12730MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHuman Normal Immunoglobulin for IV (IVIG)
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIMMUNOGLOBULINA UMANA NORMALE
    D.3.9.1CAS number 9007-83-4
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN (IV)
    D.3.9.4EV Substance CodeSUB12041MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number2500 to 20000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMethylprednisolone
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Powder and solvent for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMETILPREDNISOLONE
    D.3.9.1CAS number 83-43-2
    D.3.9.2Current sponsor codeMETHYLPREDNISOLONE
    D.3.9.3Other descriptive nameMethylprednisolone
    D.3.9.4EV Substance CodeSUB14562MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number40 to 100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 9
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisolone
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISOLONE
    D.3.9.1CAS number 50-24-8
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive namePrednisolone
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Kawasaki Disease
    Malattia di Kawasaki
    E.1.1.1Medical condition in easily understood language
    Kawasaki Disease
    Malattia di Kawasaki
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10023320
    E.1.2Term Kawasaki's disease
    E.1.2System Organ Class 10047065 - Vascular disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To establish the effectiveness and efficacy of adjunctive corticosteroid therapy combined with IVIG/aspirin for prevention of CAA in unselected patients with KD across Europe;
    Stabilire l'efficacia della terapia aggiuntiva con corticosteroidi combinata con IVIG/aspirina per la prevenzione di CAA in pazienti non selezionati con KD in Europa.
    E.2.2Secondary objectives of the trial
    To establish:
    1. the safety of adjunctive corticosteroid therapy combined with IVIG/aspirin for prevention of CAA in KD;
    2. whether adjunctive corticosteroid therapy reduces the duration of fever and length of hospitalisation for patients with KD;
    3. the incremental cost-effectiveness ratio for corticosteroid therapy, expressed as the cost per QALY gained, from cost and utility data measured via resource use forms and the Child Health Utility 9D questionnaire.
    4. the utility of the Paediatric Glucocorticoid Toxicity (pGTI) tool to assess corticosteroid toxicity.
    Stabilire:
    1. la sicurezza della terapia aggiuntiva con corticosteroidi combinata con IVIG/aspirina per la prevenzione di CAA nella KD;
    2. se la terapia aggiuntiva con corticosteroidi riduce la durata della febbre e la durata del ricovero per i pazienti con KD;
    3. il rapporto incrementale di costo-efficacia per la terapia con corticosteroidi, espresso come il costo per QALY guadagnato, dai dati di costo e utilità misurati tramite moduli di utilizzo delle risorse e questionario a 9 dimensioni sulla salute individuale dei bambini (CHUD9D - Italian).
    4. l'utilità dello strumento Pediatric Glucocorticoid Toxicity (pGTI) per valutare la tossicità dei corticosteroidi.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Pharmacometric Substudy
    Secondary analysis of pharmacodynamic (PD) endpoints for efficacy and corticosteroid toxicity (in the corticosteroid group) will be performed using a new, preliminary validated tool called the paediatric glucocorticoid toxicity index (pGTI).
    Drug dose will be taken as the input with an estimated parameter for the decay in drug effect being used as a proxy for PK (K-PD approach). The efficacy analysis will consider linear and nonlinear mixed effects models of coronary Z-score over time with multivariable covariate analysis. The model will aim to identify possible differences between groups, and dose response (IVIG and corticosteroid cumulative dosing) corrected for important covariates such as CRP, age etc. The pGTI evolution in time
    with also be modelled using either linear or nonlinear mixed effects. The composite pGTI score will be treated as both a continuous variable and we will also consider sub-score modelling to assess which items are most susceptible to change in short-course therapy, which may lead to refinement of the score itself.

    Diagnostic Biomarker Substudy
    The collection of throat swab and low volume blood samples at multiple timepoints will be invaluable for future research on the diagnosis, aetiology, pathogenesis and genetics of the disease.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Sottostudio farmacometrico
    L'analisi secondaria degli endpoint farmacodinamici (PD) per l'efficacia e la tossicità dei corticosteroidi (nel gruppo dei corticosteroidi) sarà eseguita utilizzando un nuovo, preliminarmente convalidato strumento chiamato indice pediatrico di tossicità dei glucocorticoidi (pGTI).
    La dose del farmaco sarà utilizzata come dato di input con un parametro stimato per il decadimento dell'effetto del farmaco utilizzato come proxy per la PK (approccio K-PD). L'analisi di efficacia prenderà in considerazione modelli a effetti misti lineari e non lineari di Z-score coronarico nel tempo con analisi covariata multivariata. Il modello mirerà a identificare le possibili differenze tra i gruppi e la risposta alla dose (dose cumulativa di IVIG e corticosteroidi) corretta per importanti covariate come PCR, età, ecc. L'evoluzione del pGTI nel tempo
    sarà anche modellizzato utilizzando effetti misti lineari o non lineari. Il punteggio pGTI composito sarà trattato sia come una variabile continua e prenderemo in considerazione anche la modellazione del sotto-punteggio per valutare quali elementi sono più suscettibili al cambiamento nella terapia a breve termine, il che può portare al perfezionamento del punteggio stesso.

    Sottostudio sui biomarcatori diagnostici
    La raccolta di tamponi faringei e piccoli volumi di campioni di sangue in più punti temporali sarà preziosa per la ricerca futura sulla diagnosi, l'eziologia, la patogenesi e la genetica della malattia.
    E.3Principal inclusion criteria
    1. Aged 30 days (post-natal age) to 15 years inclusive, and below the country-specific age of consent for the duration of the trial

    2. KD defined in at least one of the three following ways

    a) as per American Heart Association (AHA) criteria [1]: namely fever for at least 5 days in addition to 4 of the following 5 clinical criteria:
    i. bilateral non purulent conjunctivitis
    ii. cervical lymphadenopathy
    iii. polymorphous skin rash
    iv. changes in lips or mucosa (strawberry tongue, red cracked lips, diffuse erythematous oropharynx)
    v. extremity changes (erythema, oedema of palms and soles in initial phase, and at convalescent stage skin peeling)

    (b) OR less than 5 days of fever but all 5 clinical criteria above

    (c) OR incomplete KD cases, as per a modified*AHA definition [1], namely:
    i. children/adolescents (>1 year old) with fever greater than or equal to 5 days AND at least 2 other compatible clinical criteria as listed above; OR infants <= 1 year old with fever greater than or equal to 7 days without other explanation;
    AND for both age groups
    ii. CRP >=30 mg/L or erythrocyte sedimentation rate (ESR) >=40 mm/hr (or both)
    AND for both age groups
    iii. EITHER the presence of any 3 or more of: anaemia for age (haemoglobin < lower limit of normal reference range for local laboratory) platelet count >=450x10(9)/L or <140x10(9)/L; albumin <30 g/L; elevated ALT (> upper limit of normal reference range for local laboratory); white cell count >=15 x10(9)/L; urine >=10 white blood cells per high power field
    iv. OR abnormal echocardiogram compatible with KD but without established CAA, with >= 3 of the following suggestive features: decreased left ventricular function, mitral
    regurgitation, pericardial effusion, or dilated but non-aneurysmal coronary arteries (internal diameter 2<=Z<2.5; and not meeting the exclusion criteria for aneurysmal change as defined below).

    3. Written informed consent from appropriate legal representative(s), and assent from patients who have not reached the age of consent and will not reach the age of consent for the duration of the trial in the participating country, but are judged to have capacity for this (depending on both age and acuity of illness)

    *This definition of incomplete KD is modified from the AHA definition by firstly, the exclusion of aneurysmal coronary artery changes as the sole echo finding, since this is an exclusion criterion for KD-CAAP, and secondly the inclusion of low platelet count as well as high platelet count, as highlighted in recent European consensus SHARE guideline.

    Note that patients with KD can still be included in KD-CAAP if they have started IVIG treatment, as long as they are randomised no more than 24 hours after the IVIG infusion is initiated
    1. età compresa tra 30 giorni (età postnatale) e 15 anni inclusi.

    2. KD definita da almeno uno dei tre seguenti criteri:

    a) secondo i criteri stabiliti dall’American Heart Association (AHA) ovvero: febbre da almeno 5 giorni in aggiunta a 4 dei seguenti 5 criteri:
    i. congiuntivite bilaterale non essudativa
    ii. linfoadenopatia cervicale
    iii. esantema multiforme
    iv. alterazioni alle labbra o mucosa (lingua “a fragola”, labbra rosse screpolate, eritema orofaringeo diffuso)
    v. alterazioni delle estremità (eritema, edema palmare e plantare in fase iniziale, e, nella fase di convalescenza, desquamazione)

    b) OPPURE meno di 5 giorni di febbre ma tutti e cinque i criteri clinici sopra elencati

    c) OPPURE forma di KD incompleta (o atipica) come da definizione AHA modificata*, vale a dire:
    i. bambini/adolescenti (> 1 anno di età) con febbre per 5 o più giorni ED almeno altri 2 criteri clinici compatibili tra quelli sopra elencati; OPPURE bambini di età <= ad 1 anno con febbre per 7 o più giorni senza altra spiegazione;
    ED IN AGGIUNTA per entrambe le fasce di età:
    ii. PCR >=30 mg/L o velocità di eritrosedimentazione (VES) >=40 mm/h (o entrambi)
    E per entrambe le fasce di età:
    iii. SIA la presenza di 3 o più tra: anemia per età (emoglobina < del limite inferiore del range di normalità del laboratorio locale nella fascia di età); conta piastrinica >=450x10(9)/L o <140x10(9)/L; albumina <30 g/L; valore ALT sopra la norma (> del limite superiore del range di normalità per il laboratorio locale); leucociti >= 15x10(9)/L; urine >= 10 leucociti al maggior ingrandimento
    iv. OPPURE: alterazione dell’ecocardiogramma compatibile con KD ma non in presenza di aneurisma dell’arteria coronaria (CAA), con >=3 delle seguenti caratteristiche: ridotta funzionalità del ventricolo sinistro; rigurgito mitraico; versamento pericardico; arterie coronarie dilatate ma non aneurismatiche (diametro interno 2<=Z<2,5; senza rientrare nei criteri di esclusione per le variazioni aneurismatiche come definite di seguito

    3. Acquisizione del consenso informato firmato dal/i genitore/i o dal rappresentante legale e dell’assenso da parte del paziente che non ha raggiunto l’età per fornire il suo consenso per la partecipazione allo studio ma si ritiene abbia la capacità di farlo (in relazione anche all’età e alla gravità della malattia).

    *Questa definizione di KD incompleta o atipica è modificata rispetto alla definizione AHA principalmente perché non vengono indicate le alterazioni ecografiche causate dell’aneurisma dell’arteria coronaria come unici segnali di malattia, dato che la presenza di aneurisma è un criterio di esclusione per KD-CAAP; secondariamente per l’inclusione della bassa ed alta conta piastrinica, come evidenziato nella recente linea guida European consensus SHARE.

    Si noti che i pazienti con KD possono essere inclusi in KD-CAAP anche se hanno già iniziato un trattamento con IVIG, purché la randomizzazione sia fatta entro 24 ore da quando è iniziata l’infusione di IVIG (si vedano di seguito i criteri di esclusione).
    Sono validi i referti degli esami effettuati il giorno della randomizzazione o quello precedente.
    E.4Principal exclusion criteria
    Disease-related exclusions:
    1. This diagnosis is a second or further episode of KD.
    2. Already established CAA at screening.
    3. Severe Congestive Heart Failure or cardiogenic shock defined as the presence of hypotension and shock requiring the initiation of volume expanders.
    4. Known congenital coronary artery abnormality that would impair assessment of the primary endpoint.
    5. Suspected macrophage activation syndrome.

    Exclusions related to medications:
    6. Started IVIG more than 24 hours prior to randomisation.
    7. Known hypersensitivity to prednisolone or methylprednisolone, or known phenylketonuria to aspartame used in a formulation in an infant less than 12 weeks.
    8. Current oral, intravenous or intramuscular corticosteroid treatment for more than 3 days in previous 7 days prior to randomisation.
    9. History of previous severe reaction to any human immune globulin preparation.

    Exclusions related to general health or other issues:
    10. Active varicella zoster virus infection; or known exposure to a case of varicella within the previous 21 days prior to randomisation if known to be non-immune.
    11. Co-enrolment in another study/trial of an investigative medicinal product.
    12. Pregnant or/and breastfeeding adolescents.

    Disease-related exclusions relate to those (rare) patients who already have severe fulminant inflammation and/or shock when they are diagnosed with KD, in whom recent European consensus suggests corticosteroids and/or other immunosuppression are required [5]. Such exceptional cases represent a small minority and therefore will not substantial impact on recruitment targets.
    A blood or urine pregnancy test must be completed on the day or day before randomisation for adolescents who have begun menstruation.
    Esclusioni correlate alla malattia:
    1. Diagnosi di KD di un secondo episodio di KD o di uno successivo.
    2. CAA allo screening.
    3. Infarto miocardico congestizio severo o shock cardiogeno definito come presenza di ipotensione ed infarto richiedente l’utilizzo di espansori del volume.
    4. Nota anomalia congenita dell’arteria coronaria che possa inficiare la valutazione dell’endpoint primario.
    5. Sospetta sindrome da attivazione macrofagica (o sindrome emofagocitica).

    Esclusione correlata alle terapie:
    6. Terapia IVIG iniziata più di 24 ore prima della randomizzazione.
    7. Ipersensibilità nota al prednisolone (o prednisone) o al metilprednisolone o nota fenilchetonuria da uso di aspartame in formulazione in bambini con meno di 12 settimane.
    8. Terapia corticosteroidea orale, intravenosa o intramuscolo per più di 3 giorni nei 7 giorni precedenti la randomizzazione.
    9. Storia di reazione grave a qualsiasi preparato a base di immunoglobuline umane.

    Esclusioni in relazione allo stato di salute generale o altri problemi:
    10. Infezione attiva da virus zoster della varicella o esposizione nota a casi di varicella nei 21 giorni precedenti la randomizzazione, se è noto che il soggetto non è immunizzato.
    11. Arruolamento contemporaneo in un altro studio/sperimentazione per un prodotto medicinale sperimentale.
    12. Adolescenti in gravidanza e/o in allattamento.

    Esclusioni correlate alla malattia per quei (rari) pazienti che hanno un’infiammazione fulminante e/o shock in corso alla diagnosi di KD e che necessitano, come suggerisce l’European consensus SHARE guideline, di corticosteroidi e /o altri immunosoppressori. Questi casi eccezionali rappresentano una piccola minoranza e perciò non avranno un impatto sostanziale sugli obiettivi di reclutamento.
    Il giorno della randomizzazione o quello precedente va effettuato un test di gravidanza su sangue o urine per le adolescenti che hanno avuto le prime mestruazioni.
    E.5 End points
    E.5.1Primary end point(s)
    KD-CAAP will have two co-primary outcome measures:

    Any CAA (definition below) documented within the 12 weeks of trial follow-up (to assess overall effectiveness of the strategy of immediate corticosteroids in preventing CAA, expecting that some patients will receive rescue treatment before reaching this endpoint in both randomised groups).

    An average estimate across weeks 1, 2, and 6 of the maximum of the Z-score of the internal diameters of the proximal right coronary artery or left anterior descending coronary artery, adjusting for rescue treatment (to assess the direct efficacy of corticosteroids).
    KD-CAAP avrà due indicatori di outcome co-primari basati sulla ripetizione di ecocardiografie effettuate alle settimane 1, 2, 6 e 12:

    Qualsiasi CAA documentato entro le 12 settimane di follow-up dello studio (per valutare l’efficacia complessiva della strategia dell’utilizzo precoce di corticosteroidi nella prevenzione di CAA, prevedendo che alcuni pazienti riceveranno il trattamento di salvataggio prima che si raggiunga questo endpoint in entrambi i gruppi)

    Una media calcolata nelle settimane 1, 2 e 6 del massimo Z-score dei diametri interni dell’arteria coronaria prossimale destra o dell’arteria coronaria discendente sinistra, correggendo per il trattamento di salvataggio (per valutare l’efficacia dei corticosteroidi).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Weeks 1, 2, 6 and 12
    Settimane 1, 2, 6 e 12
    E.5.2Secondary end point(s)
    Safety
    - Serious adverse events including deaths
    - Grade 3 or 4 adverse events
    - Clinical adverse events of any grade judged related to IVIG, aspirin or corticosteroids; Efficacy
    - At each of weeks 1, 2, 6 and 12 individually, the maximum of the Z-score of the internal diameters of the proximal right coronary artery or left anterior descending coronary artery.
    - Any CAA defined using a stricter definition of a luminal internal diameter Z-score of >=2.5 alone documented within the 12 weeks of trial follow-up
    - Receipt of rescue treatment.
    - Receipt of second dose of IVIG.
    - Duration of fever after enrolment (time to temperature <38°C).
    - Daily serum concentrations of CRP from days 1-5, and at 1 and 2 weeks after enrolment, and time to normalisation of CRP (<=10mg/L).
    - Duration of hospitalisation.
    Sicurezza
    - Eventi avversi seri inclusi i decessi
    - Eventi avversi di Grado 3 o 4
    - Eventi avversi clinici di ogni grado ritenuti correlati a IVIG, aspirina o corticosteroidi; Efficacia
    - Ad ognuna delle settimane 1, 2, 6 e 12 individualmente, il massimo Z-score coronarico
    - CAA definito esclusivamente da uno z-score >= 2,5 per il diametro luminale
    - Ricevere il trattamento di salvataggio
    - Ricevere una seconda dose di IVIG
    - Durata della febbre dopo l’arruolamento (tempo a temperatura <38 °C)
    (vi) Concentrazione sierica giornaliera di PCR nell’intervallo giorno 1-giorno 5 oltre che a 1 e 2 settimane dopo l’arruolamento e tempo di normalizzazione della PCR (<=10 mg/L)
    (vii) Durata dell’ospedalizzazione
    E.5.2.1Timepoint(s) of evaluation of this end point
    Days 1, 2, 3, 4, 5 and weeks 1, 2, 6, 12; Days 1, 2, 3, 4, 5 and weeks 1, 2, 6, 12
    Giorni 1, 2, 3, 4, 5 e settimane 1, 2, 6, 12; Giorni 1, 2, 3, 4, 5 e settimane 1, 2, 6, 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Pharmacometric
    Farmacometrica
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Terapia standard (IVIG e aspirina)
    Standard of care (IVIG and aspirin only)
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA38
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Estonia
    Finland
    France
    Germany
    Ireland
    Italy
    Netherlands
    Poland
    Spain
    Sweden
    United Kingdom
    Czechia
    Greece
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of trial is defined as 12 months after the last scheduled follow-up visit of the last randomised participant. This is to ensure sufficient time for data submission, data cleaning, verification of queries, database lock and final analysis. Each site will be closed once data cleaning is completed at that site, and the relevant regulatory authorities and ethics committee will be informed.
    La fine della sperimentazione è stabilita a 12 mesi dopo ultima visita programmata di follow-up dell'ultimo paziente randomizzato, in questo modo si garantisce un tempo sufficiente per la registrazione dei dati, la pulizia dei dati, la verifica delle query, la chiusura del database e l'analisi finale dei dati. Ogni centro potrà chiudere una volta completata la pulizia dei dati e data comunicazione della conclusione dello studio alle autorità regolatorie e ai comitati etici.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 52
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 197
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 13
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2021-10-18. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Children from 30 days to 15 years inclusive
    Bambini di età compresa tra 30 giorni e 15 anni inclusi
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 210
    F.4.2.2In the whole clinical trial 262
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no arrangements for continued provision of the intervention for participants once the research has ended. This is because it is expected that by the week 12 visits all patients will have completed their corticosteroids. Participants taper their corticosteroids over 10 days upon resolution of their fever and their CRP is equal to or below 10mg/L.

    Follow-up thereafter is soley dependent on the routine follow up that would be offered as standard of clinical care.
    Non è prevista una prosecuzione della terapia sperimentale oltre il periodo dello studio in quanto ci si aspetta che alla 12a settimana tutti i pazienti abbiano completato la terapia corticosteroidea, dato che i corticosteroidi vengono ridotti per 10 giorni dalla risoluzione di febbre e con PCR uguale o minore di 10mg/L.
    Il follow-up successivo dipende unicamente dal follow-up previsto dalla normale pratica clinica dal centro.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-14
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-08-13
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:32:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA